Dexcom Stelo vs Libre 3 Plus vs Lingo: Which CGM Makes Sense for Non-Diabetics in 2026?

Why This Comparison Is Harder Than It Looks

Continuous glucose monitors (CGMs) used to be prescription tools for people with diabetes. Since 2024, the US FDA has cleared over-the-counter (OTC) sensors aimed at adults who do not use insulin, and wellness buyers now see Dexcom Stelo, Abbott Libre 3 Plus, and Abbott Lingo side by side.

These three products are not interchangeable. They differ in regulatory status, the type of feedback their apps give, and how much published accuracy data exists. Much of what circulates online—precise accuracy rankings for non-diabetic users, engagement percentages, exact "spike detection" timing—is not backed by published studies.

What Each Device Is

Dexcom Stelo was cleared by the FDA in March 2024 as the first OTC CGM in the US. It is intended for adults 18 and older who do not use insulin, uses Dexcom's G7-family sensor platform, and each sensor is worn for up to 15 days.

Abbott Lingo was cleared as an OTC device in June 2024, alongside Libre Rio. Lingo is built on Abbott's FreeStyle Libre sensor technology and is positioned as a wellness product whose app focuses on coaching and simplified feedback rather than diabetes metrics.

Libre 3 Plus is different: in the US it is a prescription diabetes device, not an OTC wellness product. Some non-diabetic users obtain it through a clinician, but it is not marketed for over-the-counter purchase.

Accuracy: What Has Actually Been Published

Accuracy is usually reported as MARD (mean absolute relative difference)—the average percentage gap between the sensor and a laboratory reference. Lower is better.

The key limitation: published accuracy studies for these sensor platforms were done in people with diabetes, not in healthy wellness users, and there is no independent head-to-head MARD comparison of Stelo, Libre 3 Plus, and Lingo in non-diabetic adults.

What does exist: a multicenter study of Dexcom's 15-day G7 sensor in 130 adults with diabetes reported an overall MARD of 8.0% against a laboratory analyzer. An independent head-to-head study in 24 adults with type 1 diabetes wore FreeStyle Libre 3, Dexcom G7, and Medtronic Simplera at the same time; against the YSI reference, MARD was 11.6% for Libre 3 and 12.0% for G7, and results shifted depending on which reference method and glucose range were used.

The practical takeaway is that both Dexcom and Abbott sensor families perform in a broadly similar accuracy range, and the differences between them are smaller than the differences created by study design. Manufacturer MARD figures are not directly comparable across brands.

App Experience: Numbers or Nudges

Stelo's app shows glucose readings and trends and is aimed at users who want to look at their own data and draw their own conclusions.

Lingo's app is built around coaching: it emphasizes simplified feedback on glucose "spikes" and suggestions for habits, rather than clinical metrics. Some people find this easier to act on; others prefer more detail.

Libre 3 Plus uses Abbott's diabetes-management software, which reports standard clinical metrics such as time in range and is designed for sharing with a care team.

App features, smartwatch support, and integrations change frequently, so check each manufacturer's current specifications before buying.

Cost

OTC sensors are generally paid out of pocket and are not covered by insurance; HSA/FSA eligibility varies by plan. List prices and subscription offers change often, so compare current manufacturer pricing rather than relying on figures quoted in reviews. Because each sensor lasts about two weeks, a month of continuous wear typically requires two sensors.

What the Research Shows for People Without Diabetes

A multicenter study of 153 healthy, non-diabetic participants wearing blinded CGMs found mean glucose of roughly 98–99 mg/dL in most age groups and a median of 96% of the day spent between 70 and 140 mg/dL. In other words, healthy people do have glucose rises after meals, and brief readings above 140 mg/dL are normal rather than a sign of disease.

A 2024 meta-analysis of 25 randomized trials found that CGM-based feedback modestly improved glucose outcomes, but most of those trials were in people with diabetes. A 2026 systematic review focused on adults without diabetes concluded that visible CGM feedback may support selected dietary changes when combined with structured education, but that large, lasting benefits and stand-alone effectiveness have not been established, and the certainty of evidence was low.

There is no evidence-based "optimal" wear schedule for non-diabetic users. Short, deliberate experiments—testing a specific meal, walk, or sleep change—tend to be more useful than open-ended wear.

Who Each Option Suits

Stelo may suit people who want to see their own numbers and are comfortable interpreting them.

Lingo may suit people who want guidance and simplified feedback more than detailed data.

Libre 3 Plus is relevant mainly if a clinician has prescribed it; it is not an OTC wellness purchase in the US.

Safety Notes

OTC CGMs are not intended for people who use insulin or who have problematic hypoglycemia, and they are not a tool for diagnosing diabetes. Sensors measure interstitial fluid, which lags behind blood glucose. If a reading does not match how you feel, or if you suspect diabetes or recurrent low blood sugar, talk with a healthcare professional rather than adjusting your diet or medication on the basis of sensor data alone.